Back to Search Start Over

Clinical whole-genome sequencing and FISH identify two different fusion partners for NUP98 in a patient with acute myeloid leukemia: A case report.

Authors :
Mojarad BA
Crees ZD
Schroeder MC
Xiang Z
Vader J
Sina J
Jacoby M
Frater JL
Duncavage EJ
Spencer DH
Lavine K
Neidich JA
Amarillo I
Source :
Cancer genetics [Cancer Genet] 2024 Jan; Vol. 280-281, pp. 1-5. Date of Electronic Publication: 2023 Nov 29.
Publication Year :
2024

Abstract

Background: Only rare cases of acute myeloid leukemia (AML) have been shown to harbor a t(8;11)(p11.2;p15.4). This translocation is believed to involve the fusion of NSD3 or FGFR1 with NUP98; however, apart from targeted mRNA quantitative PCR analysis, no molecular approaches have been utilized to define the chimeric fusions present in these rare cases.<br />Case Presentation: Here we present the case of a 51-year-old female with AML with myelodysplastic-related morphologic changes, 13q deletion and t(8;11), where initial fluorescence in situ hybridization (FISH) assays were consistent with the presence of NUP98 and FGFR1 rearrangements, and suggestive of NUP98/FGFR1 fusion. Using a streamlined clinical whole-genome sequencing approach, we resolved the breakpoints of this translocation to intron 4 of NSD3 and intron 12 of NUP98, indicating NUP98/NSD3 rearrangement as the likely underlying aberration. Furthermore, our approach identified small variants in WT1 and STAG2, as well as an interstitial deletion on the short arm of chromosome 12, which were cryptic in G-banded chromosomes.<br />Conclusions: NUP98 fusions in acute leukemia are predictive of poor prognosis. The associated fusion partner and the presence of co-occurring mutations, such as WT1, further refine this prognosis with potential clinical implications. Using a clinical whole-genome sequencing analysis, we resolved t(8;11) breakpoints to NSD3 and NUP98, ruling out the involvement of FGFR1 suggested by FISH while also identifying multiple chromosomal and sequence level aberrations.<br />Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest or financial disclosures.<br /> (Copyright © 2023. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
2210-7762
Volume :
280-281
Database :
MEDLINE
Journal :
Cancer genetics
Publication Type :
Report
Accession number :
38056049
Full Text :
https://doi.org/10.1016/j.cancergen.2023.11.001